Press releases
- Satellos Presents Preliminary Data Showing Muscle Repair and Regeneration from SAT-3247 Treatment in Canine Model of Duchenne Muscular Dystrophy (“DMD”)
- Satellos Announces Presentation at Parent Project Muscular Dystrophy (PPMD) 30th Annual Conference
- Satellos Announces Formation of Clinical Advisory Board to Support Advancing SAT-3247 in Clinical Trial Development for Duchenne Muscular Dystrophy
- Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders
- Satellos Bioscience Announces Q1 2024 Financial Results and Operational Highlights
- Satellos to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
More ▼
Key statistics
On Friday, Satellos Bioscience Inc (0ITA:STU) closed at 0.35, -26.47% below its 52-week high of 0.476, set on Feb 21, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.348 |
---|---|
High | 0.35 |
Low | 0.346 |
Bid | 0.346 |
Offer | 0.372 |
Previous close | 0.346 |
Average volume | 0.00 |
---|---|
Shares outstanding | 112.79m |
Free float | 98.73m |
P/E (TTM) | -- |
Market cap | 59.78m CAD |
EPS (TTM) | -0.1718 CAD |
Data delayed at least 15 minutes, as of Jul 05 2024.
More ▼